Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Collins, Peter William ORCID: https://orcid.org/0000-0002-6410-1324, Blanchette, V. S., Fischer, K., Bjorkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J. and Ewenstein, B. 2009. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostatis 7 (3) , pp. 413-420. 10.1111/j.1538-7836.2008.03270.x

Full text not available from this repository.

Abstract

Background: The role of prophylactic factor VIII (FVIII) to decrease hemophilic bleeding and arthropathy iswell established. The rationale for this strategy is to convert patients with severe hemophilia A to a moderate clinical phenotype by reducing time spent with a FVIII level<1 IU dL)1. Studies to date, however, have not demonstrated a strong link between FVIII level and the bleeding rate. Objectives: To assess the effect of FVIII level on break-through bleeding in patientswith severe hemophilia A on prophylaxis. Patients/methods: This study analysed data from 44 patients aged 1–6 and 99 patients aged 10–65 years with severe hemophilia A (FVIII <1 IU dL)1) who were treated with prophylactic FVIII as part of clinical studies assessing pharmacokinetics, safety and efficacy of a recombinant FVIII (Advate®). Each patient had pharmacokinetic measurements and FVIII infusions recorded, and these were used to calculate time spent with a FVIII below 1, 2 and 5 IU dL)1. Results: The data demonstrate that increasing time with a FVIII below 1 IU dL)1 is associated with increased total bleeds and hemarthroses. Lack of adherence to the intended frequency of FVIII infusion was the most important determinant of low FVIII and increased bleeding. In children aged 1–6 years, the rate of bleeding was also influenced by FVIII half-life and clearance. Conclusions: These data have important implications for the management of patients with severe hemophilia.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	bleeding; factor VIII; hemophilia A; pharmacokinetics; prophylaxis.
Publisher:	Wiley-Blackwell
ISSN:	1538-7933
Last Modified:	20 Oct 2022 08:09
URI:	https://orca.cardiff.ac.uk/id/eprint/27399

Citation Data

Cited 289 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item